Sleep Studies: Polysomnography and Home Sleep Testing

Sleep studies are diagnostic tools used to measure physiological activity during sleep, primarily to identify sleep-disordered breathing conditions such as obstructive sleep apnea. This page covers the two principal study formats — in-laboratory polysomnography and home sleep apnea testing — along with the regulatory framework governing their use, the clinical scenarios each addresses, and the criteria that determine which test is appropriate. Understanding these distinctions matters because an incorrect test selection can produce a false-negative result, delaying treatment for a condition that affects an estimated 26% of adults between ages 30 and 70, according to data cited by the American Academy of Sleep Medicine (AASM).

Definition and scope

A sleep study is a structured physiological recording performed during a full or partial sleep period to capture data on breathing patterns, oxygen saturation, cardiac rhythm, limb movements, and sleep architecture. The broader category encompasses at least four recognized test types, classified by the Centers for Medicare & Medicaid Services (CMS) under Type I through Type IV designations, based on the number of physiological channels recorded and the level of attendant supervision.

The regulatory context for pulmonary medicine frames sleep study reimbursement and coverage under Medicare Local Coverage Determinations (LCDs), specifically LCD L33718 and its associated Policy Article, which define qualifying diagnoses, required clinical pre-test documentation, and minimum channel requirements.

How it works

In-laboratory polysomnography (Type I PSG)

Full polysomnography is conducted in an accredited sleep center. The AASM publishes scoring rules that govern how raw waveform data is interpreted. The study protocol typically unfolds in the following sequence:

  1. Patient preparation: Electrode application takes 60–90 minutes. EEG leads placed according to the international 10–20 system capture cortical activity used to stage sleep (N1, N2, N3, REM).
  2. Lights-out baseline: Technologists verify signal quality across all channels before the recording period begins.
  3. Overnight recording: The study captures a minimum of 6 hours of data, though full recording windows of 7–8 hours are standard.
  4. Technologist monitoring: A registered polysomnographic technologist (RPSGT) monitors waveforms in real time, intervenes if leads detach, and scores respiratory events including apneas and hypopneas.
  5. Scoring and report generation: A board-certified sleep medicine physician interprets the scored data and generates a report calculating the Apnea-Hypopnea Index (AHI) — the number of apnea and hypopnea events per hour of sleep.

An AHI of 5–14 events per hour defines mild obstructive sleep apnea; 15–29 defines moderate; 30 or more defines severe, per AASM scoring criteria (AASM Scoring Manual, Version 3).

Home sleep apnea testing (Type III HSAT)

A portable Type III device is typically dispensed at a clinic or shipped directly to the patient. Setup involves placing a nasal cannula with a pressure transducer for airflow measurement, two respiratory effort belts (thoracic and abdominal), and a finger probe for pulse oximetry. Most modern devices auto-score results using proprietary algorithms, but physician review and interpretation remain required under CMS billing standards. Because HSAT does not record EEG, it cannot stage sleep — total recording time is used as a proxy for sleep time, which means the AHI may be underestimated relative to a full PSG.

Common scenarios

Sleep studies are indicated across a defined set of clinical presentations. The AASM Clinical Practice Guidelines identify the following primary use cases:

Decision boundaries

The choice between in-laboratory PSG and home sleep testing is not interchangeable and depends on clinical profile, comorbidities, and the specific diagnostic question being asked.

HSAT is appropriate when:
- The clinical pre-test probability of moderate-to-severe OSA is high
- The patient has no significant cardiopulmonary comorbidity (e.g., moderate-to-severe chronic obstructive pulmonary disease, congestive heart failure, or neuromuscular disease)
- The diagnostic question is limited to OSA — no parasomnias, limb movement disorders, or narcolepsy are suspected

In-laboratory PSG is required when:
- HSAT produces a technically inadequate or inconclusive result
- Comorbid cardiorespiratory disease is present that may affect oximetry or airflow interpretation
- Central sleep apnea, hypoventilation syndromes, or narcolepsy is on the differential
- A split-night protocol is planned, where the first half records diagnostic data and the second half initiates PAP titration if the AHI meets threshold (typically ≥40 events per hour in the first 2 hours, per CMS split-night criteria)

CMS requires that a face-to-face clinical evaluation documenting signs and symptoms consistent with sleep-disordered breathing precede HSAT authorization. This requirement is codified in LCD L33718. Facilities performing in-laboratory sleep studies must meet accreditation standards set by either the AASM or the Joint Commission to qualify for Medicare reimbursement.

For a broader orientation to pulmonary diagnostic services and conditions evaluated within this specialty, the pulmonary medicine overview provides context across the full scope of the field. Patients with sleep apnea as a confirmed diagnosis move from diagnostic testing into a treatment pathway that includes PAP therapy, oral appliances, or surgical intervention depending on severity and anatomy.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)